Aminoisoquinoline thrombin inhibitor with improved bioavailability
The invention relates to the compound N-(2-oxo-2-propoxyethyl)-β-phenyl-D-phenyl-alanyl-N-[(1-amino-6-iso-quinolinyl)methyl]-L-prolinamide or a pharmaceutically acceptable salt thereof, to a pharmaceutical composition comprising said compound, as well as to the use of the compound for the manufacture of a medicament for treating or for preventing thrombin mediated diseases.
1. The compound N-(2-oxo-2-propoxyethyl)-β-phenyl-D-phenylalanyl-N-[(1-amino-6-isoquinolinyl)methyl]-L-prolinamide or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 as the dihydrochloride salt.
3. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
4. A method for treating a thrombin mediated disease in a subject in need thereof, the method comprising orally administering to the subject in need thereof an effective amount of the compound according to claim 1 .
5. The compound N-(carboxymethyl)-β-phenyl-D-phenylalanyl-N-[(1-amino-6-isoquinolinyl)methyl]-L-prolinamide or a pharmaceutically acceptable salt thereof.